Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, et al. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127(16):2934–42. First consensus of expert on the list of entities and incidence threshold in the definition of ultra-rare sarcoma.

Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, et al. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open. 2021;6(3):100170. A consensus paper from the community of experts that has tried to define what should currently be the optimal care of EHE.

Rubin BP, Deyrup AT, Doyle LA. Epithelioid haemangioendothelioma, in World Health Organization Classification of Tumours. Soft Tissue and Bone Pathology and Genetics. 5th edition. Lyon, International Agency for Research on Cancer, 2020; 172–175.

Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosom Cancer. 2011;50(8):644–53. First report of the fusion gene that characterized EHE.

Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosom Cancer. 2013;52(8):775–84.

Article  CAS  PubMed  Google Scholar 

Suurmeijer AJH, Dickson BC, Swanson D, Sung YS, Zhang L, Antonescu CR. Variant WWTR1 gene fusions in epithelioid hemangioendothelioma-a genetic subset associated with cardiac involvement. Genes Chromosom Cancer. 2020;59(7):389–95.

Article  CAS  PubMed  Google Scholar 

Rosenbaum E, Jadeja B, Xu B, Zhang L, Agaram NP, Travis W, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol Off J U S Can Acad Pathol Inc. 2020;33(4):591–602. First report of the prognostic impact of different molecular alterations in EHE.

Frezza AM, Napolitano A, Miceli R, Badalamenti G, Brunello A, Buonomenna C, et al. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network. ESMO Open. 2021;6(2):100083. First description of tumor-related pain and systemic symptoms in EHE which are present in >50% of advanced EHE and have been suggested as potential prognostic factors.

Lau K, Massad M, Pollak C, Rubin C, Yeh J, Wang J, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest. 2011;140(5):1312–8.

Article  PubMed  Google Scholar 

Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci Lond Engl 1979. 2022;136(3):197–222.

CAS  Google Scholar 

Merritt N, Garcia K, Rajendran D, Lin ZY, Zhang X, Mitchell KA, et al. TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex. eLife. 2021;10:e62857.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma S, Kanai R, Pobbati AV, Li S, Che K, Seavey CN, et al. The TAZ-CAMTA1 fusion protein promotes tumorigenesis via connective tissue growth factor and Ras-MAPK signaling in epithelioid hemangioendothelioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(14):3116–26.

Article  CAS  Google Scholar 

Seligson ND, Awasthi A, Millis SZ, Turpin BK, Meyer CF, Grand’Maison A, et al. Common secondary genomic variants associated with advanced epithelioid hemangioendothelioma. JAMA Netw Open. 2019;2(10):e1912416.

Article  PubMed  PubMed Central  Google Scholar 

Driskill JH, Zheng Y, Wu BK, Wang L, Cai J, Rakheja D, et al. WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma. Genes Dev. 2021;35(7–8):495–511.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seavey CN, Pobbati AV, Hallett A, Ma S, Reynolds JP, Kanai R, et al. WWTR1(TAZ)-CAMTA1 gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis. Genes Dev. 2021;35(7–8):512–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seavey CN, Hallett A, Li S, Che K, Pobbati AV, Ma S, et al. Loss of CDKN2A cooperates with WWTR1(TAZ)-CAMTA1 gene fusion to promote tumor progression in epithelioid hemangioendothelioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;CCR-22-2497. https://doi.org/10.1158/1078-0432.

Stacchiotti S, Zuco V, Frezza AM et al. Preliminary assessment of circulating inflammatory cytokines in epithelioid hemangioendothelioma (EHE) patients and in an EHE patient-derived xenograft (PDX) after doxorubicin and sirolimus. Connective tissue society 2022 Annual Meeting proceedings, Poster 188.

Rosenberg A, Agulnik M. Epithelioid hemangioendothelioma: update on diagnosis and treatment. Curr Treat Options Oncol. 2018;19(4):19.

Article  PubMed  Google Scholar 

Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol. 2008;32(6):924–7.

Article  PubMed  Google Scholar 

Amin RMS, Hiroshima K, Kokubo T, Nishikawa M, Narita M, Kuroki M, et al. Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report. Respirol Carlton Vic. 2006;11(6):818–25.

Article  Google Scholar 

Bagan P, Hassan M, Le Pimpec BF, Peyrard S, Souilamas R, Danel C, et al. Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature. Ann Thorac Surg. 2006;82(6):2010–3.

Article  PubMed  Google Scholar 

Saada E, Saint Paul MC, Gugenheim J, Follana P, François E. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate. Oncol Res Treat. 2014;37(3):124–6.

Article  PubMed  Google Scholar 

Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol Stockh Swed. 2017;56(1):88–92.

Article  Google Scholar 

Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119(14):2639–44.

Article  CAS  PubMed  Google Scholar 

Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(1):257–63.

Article  CAS  Google Scholar 

Zheng Z, Wang H, Jiang H, Chen E, Zhang J, Xie X. Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: a case report and literature review. Medicine (Baltimore). 2017;96(45):e8507.

Article  PubMed  Google Scholar 

Radzikowska E, Szczepulska-Wójcik E, Chabowski M, Oniszh K, Langfort R, Roszkowski K. Pulmonary epithelioid haemangioendothelioma–interferon 2-alpha treatment–case report. Pneumonol Alergol Pol. 2008;76(4):281–5.

PubMed  Google Scholar 

Soape MP, Verma R, Payne JD, Wachtel M, Hardwicke F, Cobos E. Treatment of hepatic epithelioid hemangioendothelioma: finding uses for thalidomide in a new era of medicine. Case Rep Gastrointest Med. 2015;2015:326795.

PubMed  PubMed Central  Google Scholar 

Engel ER, Cournoyer E, Adams DM, Stapleton S. A retrospective review of the use of sirolimus for pediatric patients with epithelioid hemangioendothelioma. J Pediatr Hematol Oncol. 2020;42(8):e826–9.

Article  CAS  PubMed  Google Scholar 

Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, et al. Sirolimus in advanced epithelioid hemangioendothelioma: a retrospective case-series analysis from the Italian Rare Cancer Network Database. Ann Surg Oncol. 2016;23(9):2735–44.

Article  PubMed  Google Scholar 

Stacchiotti S, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, et al. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: a case-series analysis within the Italian Rare Cancer Network. Cancer. 2021;127(4):569–76. First retrospective evidence of activity of sirolimus in advanced EHE.

Schuetze SM, Ballman KV, Ganjoo KN et al. P10015/SARC033: A phase 2 trial of trametinib in patients with epithelioid hemangioendothelioma. Connective tissue society 2022 Annual Meeting proceedings, Paper 22. First prospective phase II trial with trametinib in advanced EHE.

Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TWW, et al. Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med. 2021;10(8):2645–59. Larger retrospective series describing for the first time the activity of systemic therapies in advanced EHE.

Cioffi A, Italiano A, Penel N, et al. Metastatic epithelioid hemangioendothelioma /EHE): role of systemic therapy and survival. J Clin Oncol. 2011;29(15_suppl):10079.

Article  Google Scholar 

Kayler LK, Merion RM, Arenas JD, Magee JC, Campbell DA, Rudich SM, et al. Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. Transplantation. 2002;74(1):128–30.

Article  PubMed  Google Scholar 

Hettmer S, Andrieux G, Hochrein J, Kurz P, Rössler J, Lassmann S, et al. Epithelioid hemangioendotheliomas of the liver and lung in children and adolescents. Pediatr Blood Cancer. 2017;64(12).

Riou S, Morelon E, Guibaud L, Chotel F, Dijoud F, Marec-Berard P. Efficacy of rapamycin for refractory hemangioendotheliomas in Maffucci’s syndrome. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(23):e213-215.

Article  CAS  Google Scholar 

Cohen EEW, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012;18(17):4785–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. J Immunother Cancer. 2020;8(2):e001561.

Article  PubMed  PubMed Central  Google Scholar 

Yousaf N, Maruzzo M, Judson I, Al-Muderis O, Fisher C, Benson C. Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. Anticancer Res. 2015;35(1):473–80.

PubMed  Google Scholar